Roche to acquire US-based Poseida Therapeutics

BERLIN (Reuters) – Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.

© Reuters. FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo

Stockholders will also receive a non-tradeable contingent value right (CVR) for $4 per share, representing a total deal value of up to approximately $1.5 billion, said the company.

The transaction is expected to close in the first quarter of 2025.

Source

Leave a Reply

Your email address will not be published. Required fields are marked *